Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMarin Pharmaceutical, a biopharmaceutical company, has appointed Henry Fuchs as its new senior vice president and chief medical officer.
Subscribe to our email newsletter
Dr Fuchs will replace longtime BioMarin chief medical officer, Emil Kakkis. Dr Fuchs most recently served as executive vice president and chief medical officer of Onyx Pharmaceuticals.
Dr Fuchs has received an MD degree from George Washington University and a BA degree in biochemical sciences from Harvard University.
Jean-Jacques Bienaime, CEO of BioMarin, said: “We are extremely pleased to welcome Dr Henry Fuchs to BioMarin. He is uniquely qualified to fill this important role in the company. As an experienced CMO and CEO, he has demonstrated a strength of vision and execution from the laboratory to the marketplace and will be a highly capable contributor to our ongoing scientific and business development efforts.”